New England Journal of Medicine· 2014Q1· Clinical trial

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

Lisa A. Beck, Diamant Thaçi, Jennifer D. Hamilton, Neil M.H. Graham et al.

1,410citations
Q1SCImago
2014year

Short summary

Dupilumab, a monoclonal antibody blocking IL-4 and IL-13, significantly improved moderate-to-severe atopic dermatitis in adults, leading to rapid clinical improvements and reduced itch.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Dermatology

DermatologyMedicine